These terms and conditions govern your use of the website alphaminr.com and its related services.
These Terms and Conditions (“Terms”) are a binding contract between you and Alphaminr, (“Alphaminr”, “we”, “us” and “service”). You must agree to and accept the Terms. These Terms include the provisions in this document as well as those in the Privacy Policy. These terms may be modified at any time.
Your subscription will be on a month to month basis and automatically renew every month. You may terminate your subscription at any time through your account.
We will provide you with advance notice of any change in fees.
You represent that you are of legal age to form a binding contract. You are responsible for any
activity associated with your account. The account can be logged in at only one computer at a
time.
The Services are intended for your own individual use. You shall only use the Services in a
manner that complies with all laws. You may not use any automated software, spider or system to
scrape data from Alphaminr.
Alphaminr is not a financial advisor and does not provide financial advice of any kind. The service is provided “As is”. The materials and information accessible through the Service are solely for informational purposes. While we strive to provide good information and data, we make no guarantee or warranty as to its accuracy.
TO THE EXTENT PERMITTED BY APPLICABLE LAW, UNDER NO CIRCUMSTANCES SHALL ALPHAMINR BE LIABLE TO YOU FOR DAMAGES OF ANY KIND, INCLUDING DAMAGES FOR INVESTMENT LOSSES, LOSS OF DATA, OR ACCURACY OF DATA, OR FOR ANY AMOUNT, IN THE AGGREGATE, IN EXCESS OF THE GREATER OF (1) FIFTY DOLLARS OR (2) THE AMOUNTS PAID BY YOU TO ALPHAMINR IN THE SIX MONTH PERIOD PRECEDING THIS APPLICABLE CLAIM. SOME STATES DO NOT ALLOW THE EXCLUSION OR LIMITATION OF INCIDENTAL OR CONSEQUENTIAL OR CERTAIN OTHER DAMAGES, SO THE ABOVE LIMITATION AND EXCLUSIONS MAY NOT APPLY TO YOU.
If any provision of these Terms is found to be invalid under any applicable law, such provision shall not affect the validity or enforceability of the remaining provisions herein.
This privacy policy describes how we (“Alphaminr”) collect, use, share and protect your personal information when we provide our service (“Service”). This Privacy Policy explains how information is collected about you either directly or indirectly. By using our service, you acknowledge the terms of this Privacy Notice. If you do not agree to the terms of this Privacy Policy, please do not use our Service. You should contact us if you have questions about it. We may modify this Privacy Policy periodically.
When you register for our Service, we collect information from you such as your name, email address and credit card information.
Like many other websites we use “cookies”, which are small text files that are stored on your computer or other device that record your preferences and actions, including how you use the website. You can set your browser or device to refuse all cookies or to alert you when a cookie is being sent. If you delete your cookies, if you opt-out from cookies, some Services may not function properly. We collect information when you use our Service. This includes which pages you visit.
We use Google Analytics and we use Stripe for payment processing. We will not share the information we collect with third parties for promotional purposes. We may share personal information with law enforcement as required or permitted by law.
|
ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
|
|
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
|
WISCONSIN
|
|
|
(State of Incorporation)
|
|
(IRS Employer Identification Number)
|
TITLE OF EACH CLASS
|
TRADING SYMBOL(S)
|
NAME OF EACH EXCHANGE
ON WHICH REGISTERED
|
|
Accelerated Filer
☐
|
Non-Accelerated Filer
☐
|
|
Smaller Reporting Company
|
Emerging Growth Company
|
|
|
5
|
|||
5
|
|||
5
|
|||
5
|
|||
6
|
|||
6
|
|||
6
|
|||
7
|
|||
7
|
|||
7
|
|||
7
|
|||
8
|
|||
8
|
|||
8
|
|||
8
|
|||
8
|
|||
10
|
|||
10
|
|||
18
|
|||
18
|
|||
19
|
|||
19
|
|||
19
|
|||
21
|
|||
21
|
|||
22
|
|||
22
|
|||
29
|
|||
31
|
|||
61
|
|||
61
|
|||
62
|
|||
63 | |||
63 | |||
63 | |||
63 | |||
63 | |||
63 | |||
64 | |||
64 | |||
64 | |||
70 | |||
70 | |||
70 | |||
64 | |||
71 |
Item 1. |
Business.
|
|
● |
flavors, flavor enhancers, ingredients, extracts, and bionutrients;
|
|
● |
essential oils;
|
|
● |
dehydrated vegetables and other food ingredients;
|
|
● |
natural and synthetic food and beverage colors;
|
|
● |
cosmetic colors and ingredients;
|
|
● |
pharmaceutical and nutraceutical excipients and ingredients; and
|
|
● |
technical colors, specialty colors, and specialty dyes and pigments.
|
● |
Sensient Food Colors (food and beverage colors);
|
● |
Sensient Pharmaceutical Coating Systems (pharmaceutical and nutraceutical colors and coatings);
|
● |
Sensient Cosmetic Technologies (cosmetic colors, ingredients, and systems); and
|
● |
Sensient Industrial Colors (paper colors; and industrial colors for plastics, leather, wood stains, antifreeze, landscaping, and other uses).
|
|
• |
Flavors & Extracts.
Competition in the flavors, extracts, and ingredients industries continues to have an ever-increasing global
nature. Most of the Company’s customers do not buy all of their flavor and ingredients products from a single supplier, and the Company does not compete with a single supplier in all product categories. Competition for the supply of
flavors, extracts, and essential oils is based on the development of customized ingredients for new and reformulated customer products as well as on quality, customer service, and price.
Competition
to supply dehydrated vegetable products is present through several large and small domestic competitors as well as competitors from other countries. Competition for the supply of dehydrated vegetables is based principally on product
quality, customer service, and price.
|
|
• |
Color.
Competition in the color market is diverse, with the majority of the Company’s competitors specializing in either synthetic
dyes and pigments or natural colors or coloring foodstuffs (in Europe). The Company believes that it gains a competitive advantage as the only major basic manufacturer of a full range of color products, including synthetic dyes and
pigments as well as natural colors. Competition in the supply of cosmetic colors and ingredients, and pharmaceutical and nutraceutical ingredients and excipients is based on the development of customized products and solutions as well as
quality, customer service, and price. The Company believes that its reputation and capacity as a color producer as well as its product development and applications expertise give it a competitive advantage in these markets.
|
|
• |
Asia Pacific.
The Company offers a broad array of products to customers through the Asia Pacific Group. Competition is based upon
reliability in product quality, service, and price as well as technical support available to customers.
|
|
• |
Implemented and regularly updated a company-wide COVID-19 policy, which includes (i) information regarding COVID-19, its symptoms, how to prevent its transmission, and what
to do if you may or do have COVID-19; (ii) requirements around hygiene, sanitation, and social distancing; (iii) travel guidelines; and (iv) expectations of employees working remotely;
|
|
• |
CEO town hall videos regularly shown to entire workforce include discussions of the expectations around illness prevention, hygiene, sanitation, social distancing, and
elevating issues to the CEO as well as encouraging all employees to become vaccinated with appropriate booster shots;
|
|
• |
Implemented and continually updated an “Are You Sick” Flow Chart (under the guidance of Director Dr. Donald Landry) setting forth a simple summary of required actions when an
employee feels ill or may have had possible exposure to COVID-19;
|
|
• |
Implemented a vaccine mandate in the United States and elsewhere, as permitted by local law, for all positions at the director level and above, and all customer-facing sales
roles.
|
|
• |
Produced a video Q&A session with the CEO and Director Dr. Donald Landry to discuss the benefits of the vaccine and to dispel myths concerning its safety and efficacy,
which was mandatory viewing for all employees;
|
|
• |
Purchase, distribution, and use of Corporate-sponsored COVID-19 test kits (PCR-based) with next day results in most locations to ensure business continuity and employee peace
of mind;
|
|
• |
Checklist for contact tracing, proactive cleaning, and work-relatedness assessment;
|
|
• |
Decontamination and sanitation protocols, including regular cleaning of work areas;
|
|
• |
Protective on-site measures to prevent transmission, that have evolved to take into account the fully vaccinated status of many employees and updated guidance concerning the
transmission of the virus, such as face coverings; visitor health screenings; manufacture and provision of hand sanitizer; reconfiguration of work areas to maximize distance between employees; installation of plexiglass barriers;
mandatory spacing in break rooms, conference rooms, and common areas; controlled traffic patterns to maximize distance; alternative work and break schedules; use of video conferencing; and signage in offices and facilities concerning
hygiene;
|
|
• |
Rapid conversion to remote work during government-mandated lockdowns and case surges for employees capable of performing work from home;
|
|
• |
“Return to Office” checklist to ensure safe transition of employees back to office setting;
|
|
• |
Use of Quality team to audit effectiveness of sanitation efforts in production and non-production areas, including office spaces, breakrooms, and laboratories;
|
|
• |
Developed a COVID-19 Response and Preparedness Plan template for local implementation;
|
|
• |
Notification to employees when positive cases in the local workforce occur;
|
|
• |
Designated key contacts leading COVID-19 response at local and Corporate level;
|
|
• |
Reasonable accommodation of employees at high risk for developing a severe case of COVID-19;
|
|
• |
Disciplinary action for employees violating social distancing and mask rules;
|
|
• |
COVID-19 in-house testing tracker to monitor COVID-19 testing and test kit inventory;
|
|
• |
Development of a vaccination roster for employees based in the United States; and
|
|
• |
Global COVID-19 tracker to monitor positive cases, quarantined employees, and other COVID-related absenteeism.
|
Item 1A. |
Risk Factors.
|
• |
The
coronavirus/COVID-19 has significantly impacted worldwide economic conditions and could adversely affect
our results and financial condition.
|
• |
Intense competition with our competitors may result in reduced sales and profitability.
|
• |
Intense competition among our customers and their competitors may result in reduced sales and profitability for our customers and us.
|
• |
In some product lines, most of our sales are made to a relatively small number of customers; if we lose any of those customers, sales and operating
results could decline.
|
• |
Consolidation has resulted in customers with increased buying power, which can affect our profitability.
|
• |
Our sales and profitability are affected by changing consumer preferences, changing regulations and technologies, and our ability and our customers’
ability to make and sell to consumers in highly competitive markets.
|
• |
The financial condition of our customers may adversely affect their ability to buy products from us at current levels, to accept price increases, or to
pay for products that they have already purchased.
|
• |
If we do not maintain an efficient cost structure, our profitability could decrease.
|
• |
A disruption in our supply chain could adversely affect our profitability.
|
•
|
A disruption in our manufacturing operations could adversely affect our profitability.
|
• |
Our ability to efficiently manage inventory may not be as effective as we anticipate and may adversely impact our performance.
|
• |
Raw material, energy, labor, and transportation cost volatility, including inflation in prices due to ongoing supply chain challenges and other
macroeconomic forces, may reduce our profitability.
|
• |
The impact of currency exchange rate fluctuation may negatively affect our results.
|
•
|
Operating in foreign countries and emerging markets exposes us to increased risks, including economic, political, security, and international operation
risks.
|
•
|
The impact of tariffs and other trade barriers may negatively affect our results.
|
• |
Various stakeholders’ increasing and changing expectations and new regulations with respect to Environmental, Social, and Governance (ESG) matters may
impose additional costs on us or expose us to additional risks.
|
• |
The transition away from LIBOR could negatively impact our borrowing costs.
|
• |
World events and natural disasters are beyond our control and could affect our results.
|
• |
Many of our products are used in items for human consumption and contact. We may be subject to product liability claims and product recalls, which could
negatively impact our profitability and corporate image.
|
• |
There are an enormous number of laws and regulations applicable to us, our suppliers, and our customers across all of our business lines. Compliance with
these legal requirements is costly to us and can affect our operations as well as those of our suppliers and customers. Failure to comply could also be costly and disruptive.
|
• |
Environmental compliance may be costly to us.
|
• |
We could be adversely affected by violations of anti-bribery and anti-corruption laws and regulations.
|
• |
Changes in tax rates or tax laws could expose us to additional tax liabilities that may negatively affect our results.
|
• |
We depend on certain key personnel, and the loss of these persons may harm our business, including the loss of trade secrets.
|
• |
We face risks associated with strategic transactions that we have completed and may pursue in the future, which could adversely affect our operating
results.
|
• |
Our recent restructurings and the operational improvement plan may not be as effective as we anticipated and we may fail to realize the expected cost
savings.
|
•
|
Our ability to protect our intellectual property rights is key to our performance.
|
• |
Our ability to successfully maintain and upgrade our information technology systems, and to respond effectively to failures, disruptions, compromises, or
breaches of our information technology systems, may adversely affect our competitiveness and profitability.
|
Item 1B. |
Unresolved Staff Comments.
|
Item 2. |
Properties.
|
Item 3. |
Legal Proceedings.
|
Item 4. |
Mine Safety Disclosure.
|
Name
|
Age
|
Position
|
Paul Manning
|
47
|
Chairman, President, and Chief Executive Officer
|
Amy M. Agallar
|
44
|
Vice President and Treasurer
|
Michael C. Geraghty
|
60
|
President, Color Group
|
Thierry Hoang
|
39
|
Vice President, Asia Pacific Group
|
Amy Schmidt Jones
|
52
|
Vice President, Human Resources and Senior Counsel
|
John J. Manning
|
53
|
Senior Vice President, General Counsel, and Secretary
|
E. Craig Mitchell
|
57
|
President, Flavors and Extracts Group
|
Stephen J. Rolfs
|
57
|
Senior Vice President and Chief Financial Officer
|
Tobin Tornehl
|
48
|
Vice President, Controller and Chief Accounting Officer
|
|
• |
Mr. Paul Manning has held his present office since April 21, 2016, and previously served as President and Chief Executive Officer (2014 – April 2016).
|
|
• |
Ms. Agallar has held her present office since January 9, 2019. Prior to joining the Company, Ms. Agallar was Director – Business Development CIS of Modine Manufacturing (June
2018 – January 2019), and Director – Global Treasury Operations of Modine Manufacturing (2011– June 2018).
|
|
• |
Mr. Hoang has held his present office since June 1, 2018, and previously served as a General Manager, Business Unit Manager, and Sales Account Manager for Sensient Cosmetics
in France and Asia Pacific (2009 – May 2018).
|
|
• |
Ms. Jones has held her present office since April 2, 2018. Prior to joining the Company, Ms. Jones was a partner of Michael Best & Friedrich LLP (1998 – March 2018).
|
|
• |
Mr. John J. Manning has held his present office since April 21, 2016, and previously served as Vice President and Assistant General Counsel (2013 – April 2016).
|
|
• |
Mr. Mitchell has held his present office since September 17, 2018. Prior to joining the Company, Mr. Mitchell served as President and Chief Operating Officer of Sekisui
Specialty Chemical America, LLC (April 2016 – September 2018), and Vice President of Sales, Americas of Celanese Corporation (2013 – April 2016).
|
|
• |
Mr. Tornehl has held his present office since November 10, 2018, and previously served as Director, Finance (2008 – November 2018).
|
Item 5. |
Market for the Registrant’s Common Equity, Related Stockholder Matters, and Issuer Purchases of Equity
Securities.
|
Period
|
Total
Number of
Shares
Purchased
|
Average
Price
Paid per
Share
|
Total Number of
shares purchased
as part of
publicly
announced plans
or programs
|
Maximum number
of shares that may
yet be purchased
under the plans or
programs
|
||||||||||||
October 1 to October 31, 2021
|
46,200
|
$
|
93.65
|
46,200
|
1,796,233
|
|||||||||||
November 1 to November 30, 2021
|
46,200
|
100.20
|
46,200
|
1,750,033
|
||||||||||||
December 1 to December 31, 2021
|
17,052
|
98.59
|
17,052
|
1,732,981
|
||||||||||||
Total
|
109,452
|
109,452
|
December
31, 2016
|
December
31, 2017
|
December
31, 2018
|
December
31, 2019
|
December
31, 2020
|
December
31, 2021
|
|||||||||||||||||||
Sensient Technologies Corporation
|
$
|
100
|
$
|
95
|
$
|
74
|
$
|
89
|
$
|
102
|
$
|
141
|
||||||||||||
S&P Midcap Specialty Chemicals Index
|
100
|
107
|
102
|
120
|
129
|
154
|
||||||||||||||||||
S&P Midcap Food Products Index
|
100
|
105
|
98
|
115
|
126
|
147
|
||||||||||||||||||
S&P 500 Index
|
100
|
122
|
116
|
153
|
181
|
233
|
Item 6. |
[Reserved]
|
Item 7. |
Management’s Discussion and Analysis of Financial Condition and Results of Operations.
|
2021
|
2020
|
|||||||
Rate before divestiture and discrete items
|
24.3
|
%
|
24.8
|
%
|
||||
Divestiture & other related costs impact
|
4.2
|
%
|
0.3
|
%
|
||||
Discrete items
|
(3.9
|
%)
|
(4.5
|
%)
|
||||
Reported effective tax rate
|
24.6
|
%
|
20.6
|
%
|
Twelve Months Ended December 31,
|
||||||||||||
(In thousands except per share amounts)
|
2021
|
2020
|
% Change
|
|||||||||
Revenue (GAAP)
|
$
|
1,380,264
|
$
|
1,332,001
|
3.6
|
%
|
||||||
Revenue of the divested product lines
|
(30,062
|
)
|
(113,553
|
)
|
||||||||
Adjusted revenue
|
$
|
1,350,202
|
1,218,448
|
10.8
|
%
|
|||||||
Operating Income (GAAP)
|
$
|
170,028
|
$
|
152,656
|
11.4
|
%
|
||||||
Divestiture & other related costs – Cost of products sold
|
86
|
1,795
|
||||||||||
Divestiture & other related costs – Selling and administrative expenses
|
14,052
|
10,360
|
||||||||||
Operating income of the divested product lines
|
(1,880
|
)
|
(7,580
|
)
|
||||||||
Operational improvement plan – Cost of products sold
|
-
|
35
|
||||||||||
Operational improvement plan – Selling and administrative (income) expenses
|
(1,895
|
)
|
3,304
|
|||||||||
COVID-19 employee payment– Cost of products sold
|
-
|
1,036
|
||||||||||
COVID-19 employee payment – Selling and administrative expenses
|
-
|
1,986
|
||||||||||
Adjusted operating income
|
$
|
180,391
|
$
|
163,592
|
10.3
|
%
|
||||||
Net Earnings (GAAP)
|
$
|
118,745
|
$
|
109,472
|
8.5
|
%
|
||||||
Divestiture & other related costs, before tax
|
14,138
|
12,155
|
||||||||||
Tax impact of divestiture & other related costs
|
2,092
|
(2,605
|
)
|
|||||||||
Net earnings of the divested product lines, before tax
|
(1,880
|
)
|
(7,580
|
)
|
||||||||
Tax impact of the divested product lines
|
460
|
1,945
|
||||||||||
Operational improvement plan (income) costs, before tax
|
(1,895
|
)
|
3,339
|
|||||||||
Tax impact of operational improvement plan
|
471
|
(826
|
)
|
|||||||||
COVID-19 employee payment, before tax
|
-
|
3,022
|
||||||||||
Tax impact of COVID-19 employee payment
|
-
|
(675
|
)
|
|||||||||
Adjusted net earnings
|
$
|
132,131
|
$
|
118,247
|
11.7
|
%
|
||||||
Diluted Earnings Per Share (GAAP)
|
$
|
2.81
|
$
|
2.59
|
8.5
|
%
|
||||||
Divestiture & other related costs, net of tax
|
0.38
|
0.23
|
||||||||||
Results of operations of the divested product lines, net of tax
|
(0.03
|
)
|
(0.13
|
)
|
||||||||
Operational improvement plan, net of tax
|
(0.03
|
)
|
0.06
|
|||||||||
COVID-19 employee payment, net of tax
|
-
|
0.06
|
||||||||||
Adjusted diluted earnings per share
|
$
|
3.13
|
$
|
2.79
|
12.2
|
%
|
Twelve Months Ended December 31, 2021
|
||||||||||||||||
Total
|
Foreign
Exchange
Rates
|
Adjustments
(1)
|
Adjusted Local Currency
|
|||||||||||||
Revenue
|
||||||||||||||||
Flavors & Extracts
|
(0.4
|
%)
|
1.6
|
%
|
(11.4
|
%)
|
9.4
|
%
|
||||||||
Color
|
8.8
|
%
|
2.1
|
%
|
(2.7
|
%)
|
9.4
|
%
|
||||||||
Asia Pacific
|
11.6
|
%
|
1.7
|
%
|
(0.2
|
%)
|
10.1
|
%
|
||||||||
Total Revenue
|
3.6
|
%
|
1.8
|
%
|
(7.3
|
%)
|
9.1
|
%
|
||||||||
Operating Income
|
||||||||||||||||
Flavors & Extracts
|
8.4
|
%
|
1.2
|
%
|
(8.0
|
%)
|
15.2
|
%
|
||||||||
Color
|
7.9
|
%
|
2.6
|
%
|
0.5
|
%
|
4.8
|
%
|
||||||||
Asia Pacific
|
19.3
|
%
|
(1.8
|
%)
|
(0.5
|
%)
|
21.6
|
%
|
||||||||
Corporate & Other
|
3.7
|
%
|
0.0
|
%
|
(18.4
|
%)
|
22.1
|
%
|
||||||||
Total Operating Income
|
11.4
|
%
|
2.1
|
%
|
1.0
|
%
|
8.3
|
%
|
||||||||
Diluted Earnings per Share
|
8.5
|
%
|
1.9
|
%
|
(3.4
|
%)
|
10.0
|
%
|
(1)
|
For Revenue, adjustments consist of revenues of the divested product lines. For Operating Income and Diluted Earnings per Share, adjustments consist of the
results of the divested product lines, divestitures & other related costs, operational improvement plan costs and income, and the 2020 one-time COVID-19 employee payment.
|
Item 7A. |
Quantitative and Qualitative Disclosures about Market Risk.
|
|
Years Ended December 31,
|
|||||||||||
(In thousands except per share amounts)
|
2021
|
2020
|
2019
|
|||||||||
Revenue
|
$
|
|
$
|
|
$
|
|
||||||
Cost of products sold
|
|
|
|
|||||||||
Selling and administrative expenses
|
|
|
|
|||||||||
Operating income
|
|
|
|
|||||||||
Interest expense
|
|
|
|
|||||||||
Earnings before income taxes
|
|
|
|
|||||||||
Income taxes
|
|
|
|
|||||||||
Net earnings
|
$
|
|
$
|
|
$
|
|
||||||
|
||||||||||||
Earnings per common share:
|
||||||||||||
Basic
|
$
|
|
$
|
|
$
|
|
||||||
Diluted
|
$
|
|
$
|
|
$
|
|
||||||
|
||||||||||||
Weighted average number of common shares outstanding:
|
||||||||||||
Basic
|
|
|
|
|||||||||
Diluted
|
|
|
|
(In thousands)
|
Years Ended December 31,
|
|||||||||||
|
2021
|
2020
|
2019
|
|||||||||
Net earnings
|
$
|
|
$
|
|
$
|
|
||||||
Cash flow hedges adjustment, net of tax expense (benefit) of ($
|
(
|
)
|
|
(
|
)
|
|||||||
Pension adjustment, net of tax expense (benefit) of $
|
|
(
|
)
|
(
|
)
|
|||||||
Foreign currency translation on net investment hedges
|
|
(
|
)
|
|
||||||||
Tax effect of current year activity on net investment hedges
|
(
|
)
|
|
(
|
)
|
|||||||
Foreign currency translation on long-term intercompany loans
|
|
(
|
)
|
(
|
)
|
|||||||
Tax effect of current year activity on intercompany long-term loans
|
(
|
)
|
|
(
|
)
|
|||||||
Reclassification of cumulative translation to net earnings
|
|
(
|
)
|
|
||||||||
Other foreign currency translation
|
(
|
)
|
|
|
||||||||
Total comprehensive income
|
$
|
|
$
|
|
$
|
|
(In thousands except share and per share amounts)
|
December 31,
|
|||||||
|
2021
|
2020
|
||||||
Assets
|
||||||||
Current Assets:
|
||||||||
Cash and cash equivalents
|
$
|
|
$
|
|
||||
Trade accounts receivable
|
|
|
||||||
Inventories
|
|
|
||||||
Prepaid expenses and other current assets
|
|
|
||||||
Assets held for sale
|
|
|
||||||
Total current assets
|
|
|
||||||
Other assets
|
|
|
||||||
Deferred tax assets
|
|
|
||||||
Intangible assets, net
|
|
|
||||||
Goodwill
|
|
|
||||||
Property, Plant, and Equipment:
|
||||||||
Land
|
|
|
||||||
Buildings
|
|
|
||||||
Machinery and equipment
|
|
|
||||||
Construction in progress
|
|
|
||||||
|
|
|
||||||
Less accumulated depreciation
|
(
|
)
|
(
|
)
|
||||
|
|
|
||||||
Total assets
|
$
|
|
$
|
|
||||
|
||||||||
Liabilities and Shareholders’ Equity
|
||||||||
Current Liabilities:
|
||||||||
Trade accounts payable
|
$
|
|
$
|
|
||||
Accrued salaries, wages, and withholdings from employees
|
|
|
||||||
Other accrued expenses
|
|
|
||||||
Income taxes
|
|
|
||||||
Short-term borrowings
|
|
|
||||||
Liabilities held for sale
|
|
|
||||||
Total current liabilities
|
|
|
||||||
Deferred tax liabilities
|
|
|
||||||
Other liabilities
|
|
|
||||||
Accrued employee and retiree benefits
|
|
|
||||||
Long-term debt
|
|
|
||||||
Shareholders’ Equity:
|
||||||||
Common stock, par value $
|
|
|
||||||
Additional paid-in capital
|
|
|
||||||
Earnings reinvested in the business
|
|
|
||||||
Treasury stock,
|
(
|
)
|
(
|
)
|
||||
Accumulated other comprehensive loss
|
(
|
)
|
(
|
)
|
||||
|
|
|
||||||
Total liabilities and shareholders’ equity
|
$
|
|
$
|
|
(In thousands)
|
Years ended December 31,
|
|||||||||||
|
2021
|
2020
|
2019
|
|||||||||
Cash Flows from Operating Activities
|
||||||||||||
Net earnings
|
$
|
|
$
|
|
$
|
|
||||||
Adjustments to arrive at net cash provided by operating activities:
|
||||||||||||
Depreciation and amortization
|
|
|
|
|||||||||
Share-based compensation expense (income)
|
|
|
(
|
)
|
||||||||
Net loss (gain) on assets
|
|
(
|
)
|
(
|
)
|
|||||||
Loss on divestitures and other charges
|
|
|
|
|||||||||
Deferred income taxes
|
(
|
)
|
(
|
)
|
(
|
)
|
||||||
Changes in operating assets and liabilities:
|
||||||||||||
Trade accounts receivable
|
(
|
)
|
(
|
)
|
|
|||||||
Inventories
|
(
|
)
|
|
|
||||||||
Prepaid expenses and other assets
|
(
|
)
|
(
|
)
|
|
|||||||
Trade accounts payable and other accrued expenses
|
|
|
(
|
)
|
||||||||
Accrued salaries, wages, and withholdings from employees
|
|
|
(
|
)
|
||||||||
Income taxes
|
|
|
(
|
)
|
||||||||
Other liabilities
|
|
|
|
|||||||||
Net cash provided by operating activities
|
|
|
|
|||||||||
|
||||||||||||
Cash Flows from Investing Activities
|
||||||||||||
Acquisition of property, plant, and equipment
|
(
|
)
|
(
|
)
|
(
|
)
|
||||||
Proceeds from sale of assets
|
|
|
|
|||||||||
Proceeds from divestiture of businesses
|
|
|
|
|||||||||
Acquisition of new business
|
(
|
)
|
|
|
||||||||
Other investing activities
|
|
|
(
|
)
|
||||||||
Net cash used in investing activities
|
(
|
)
|
(
|
)
|
(
|
)
|
||||||
|
||||||||||||
Cash Flows from Financing Activities
|
||||||||||||
Proceeds from additional borrowings
|
|
|
|
|||||||||
Debt payments
|
(
|
)
|
(
|
)
|
(
|
)
|
||||||
Purchase of treasury stock
|
(
|
)
|
|
|
||||||||
Dividends paid
|
(
|
)
|
(
|
)
|
(
|
)
|
||||||
Other financing activities
|
(
|
)
|
(
|
)
|
(
|
)
|
||||||
Net cash used in financing activities
|
(
|
)
|
(
|
)
|
(
|
)
|
||||||
|
||||||||||||
Effect of exchange rate changes on cash and cash equivalents
|
(
|
)
|
|
|
||||||||
|
||||||||||||
Net increase (decrease) in cash and cash equivalents
|
|
|
(
|
)
|
||||||||
Cash and cash equivalents at beginning of year
|
|
|
|
|||||||||
|
||||||||||||
Cash and cash equivalents at end of year
|
$
|
|
$
|
|
$
|
|
||||||
|
||||||||||||
Cash paid during the year for:
|
||||||||||||
Interest
|
$
|
|
$
|
|
$
|
|
||||||
Income taxes
|
|
|
|
|||||||||
Capitalized interest
|
|
|
|
(In thousands except share and per share amounts)
|
Common
|
Additional
Paid-in
|
Earnings
Reinvested
in the
|
Treasury Stock
|
Accumulated
Other
Comprehensive
|
|||||||||||||||||||
|
Stock
|
Capital
|
Business
|
Shares
|
Amount
|
(Loss) Income
|
||||||||||||||||||
Balances at December 31, 2018
|
$
|
|
$
|
|
$
|
|
|
$
|
(
|
)
|
$
|
(
|
)
|
|||||||||||
Net earnings
|
|
|||||||||||||||||||||||
Other comprehensive income
|
|
|||||||||||||||||||||||
Cash dividends paid – $
|
(
|
)
|
||||||||||||||||||||||
Share-based compensation
|
(
|
)
|
||||||||||||||||||||||
Non-vested stock issued upon vesting
|
(
|
)
|
(
|
)
|
|
|||||||||||||||||||
Benefit plans
|
|
(
|
)
|
|
||||||||||||||||||||
Other
|
(
|
)
|
|
(
|
)
|
|
|
|||||||||||||||||
Balances at December 31,
2019
|
|
|
|
|
(
|
)
|
(
|
)
|
||||||||||||||||
Net earnings
|
|
|||||||||||||||||||||||
Other comprehensive income
|
|
|||||||||||||||||||||||
Cash dividends paid – $
|
(
|
)
|
||||||||||||||||||||||
Share-based compensation
|
|
|||||||||||||||||||||||
Non-vested stock issued upon vesting
|
(
|
)
|
(
|
)
|
|
|||||||||||||||||||
Benefit plans
|
|
(
|
)
|
|
||||||||||||||||||||
Other
|
(
|
)
|
(
|
) |
|
(
|
)
|
|||||||||||||||||
Balances at December 31,
2020
|
|
|
|
|
(
|
)
|
(
|
)
|
||||||||||||||||
Net earnings
|
|
|||||||||||||||||||||||
Other comprehensive loss
|
(
|
)
|
||||||||||||||||||||||
Cash dividends paid – $
|
(
|
)
|
||||||||||||||||||||||
Share-based compensation
|
|
|||||||||||||||||||||||
Non-vested stock issued upon vesting
|
(
|
)
|
(
|
)
|
|
|||||||||||||||||||
Benefit plans
|
|
(
|
)
|
|
||||||||||||||||||||
Purchase of treasury stock |
|
(
|
) | |||||||||||||||||||||
Other
|
(
|
)
|
|
(
|
)
|
|||||||||||||||||||
Balances at December 31,
2021
|
$
|
|
$
|
|
$
|
|
|
$
|
(
|
)
|
$
|
(
|
)
|
• |
Identification of the contract, or contracts, with a customer
|
• |
Identification of the performance obligations in the contract
|
• |
Determination of the transaction price
|
• |
Allocation of the transaction price to the performance obligations in the contract
|
• |
Recognition of revenue when, or as, the Company satisfies the performance obligations
|
|
Years Ended December 31,
|
|||||||||||
(In thousands except per share amounts)
|
2021
|
2020
|
2019
|
|||||||||
Numerator:
|
||||||||||||
Net earnings
|
$
|
|
$
|
|
$
|
|
||||||
Denominator:
|
||||||||||||
Denominator for basic EPS - weighted average common shares
|
|
|
|
|||||||||
Effect of dilutive securities
|
|
|
|
|||||||||
Denominator for diluted EPS - diluted weighted average shares outstanding
|
|
|
|
|||||||||
|
||||||||||||
Earnings per Common Share:
|
||||||||||||
Basic
|
$
|
|
$
|
|
$
|
|
||||||
Diluted
|
$
|
|
$
|
|
$
|
|
(In thousands)
|
Allowance for
Doubtful Accounts
|
|||
Balance at December 31,
2019
|
$
|
|
||
Adoption of ASU 2016-13
|
|
|||
Provision for expected credit losses
|
|
|||
Accounts written off
|
(
|
)
|
||
Divestitures
|
(
|
)
|
||
Translation and other activity
|
(
|
)
|
||
Balance at December 31,
2020
|
$
|
|
||
Provision for expected credit losses
|
|
|||
Accounts written off
|
(
|
) | ||
Translation and other activity
|
(
|
) | ||
Balance at December 31, 2021 | $ |
|
|
2021
|
2020
|
||||||||||||||||||
(In thousands except weighted average amortization years)
|
Weighted
Average
Amortization
Years
|
Cost
|
Accumulated
Amortization
|
Cost
|
Accumulated
Amortization
|
|||||||||||||||
|
||||||||||||||||||||
Technological know-how
|
|
$
|
|
$
|
(
|
)
|
$
|
|
$
|
(
|
)
|
|||||||||
Customer relationships
|
|
|
(
|
)
|
|
(
|
)
|
|||||||||||||
Patents, trademarks, non-compete agreements, and other
|
|
|
(
|
)
|
|
(
|
)
|
|||||||||||||
Total finite-lived intangibles
|
|
$
|
|
$
|
(
|
)
|
$
|
|
$
|
(
|
)
|
(In thousands)
|
Flavors &
Extracts
|
Color
|
Asia Pacific
|
Consolidated
|
||||||||||||
Balance as of
December 31
,
2019
|
$
|
|
$
|
|
$
|
|
$
|
|
||||||||
Currency translation impact
|
|
|
|
|
||||||||||||
Goodwill related to divestitures
(1)
|
|
|
|
|
||||||||||||
Balance as of
December 31
,
2020
|
$
|
|
$
|
|
$
|
|
$
|
|
||||||||
Currency translation impact
|
(
|
)
|
|
(
|
)
|
(
|
)
|
|||||||||
Goodwill related to divestitures
(2)
|
(
|
)
|
|
|
(
|
)
|
||||||||||
Acquisitions
(3)
|
|
|
|
|
||||||||||||
Balance as of
December 31
,
2021
|
$
|
|
$
|
|
$
|
|
$
|
|
(1) |
|
(2) |
|
|
(3) |
|
(In
thousand
s)
|
||||
Year ending December
31,
|
||||
2022
|
$
|
|
||
2023
|
|
|||
2024
|
|
|||
2025
|
|
|||
2026
|
|
|||
Thereafter
|
|
|||
Total lease payments
|
|
|||
Less imputed interest
|
(
|
)
|
||
Present value of lease liabilities
|
$
|
|
(In thousands)
|
2021
|
2020
|
||||||
|
$
|
|
$
|
|
||||
|
|
|
||||||
|
|
|
||||||
|
|
|
||||||
|
|
|
||||||
|
|
|
||||||
|
|
|
||||||
|
|
|
||||||
|
|
|
||||||
Term loan
|
|
|
||||||
Revolving Credit Facilities
|
|
|
||||||
Various other notes
|
|
|
||||||
Total debt
|
|
|
||||||
Less debt fees
|
(
|
)
|
(
|
)
|
||||
Less current portion
|
(
|
)
|
(
|
)
|
||||
Total long-term debt
|
$
|
|
$
|
|
(In
thousand
s)
|
||||
Year ending December
31,
|
||||
2022
|
$
|
|
||
2023
|
|
|||
2024
|
|
|||
2025
|
|
|||
2026
|
|
|||
Thereafter
|
|
|||
Total long-term debt maturities
|
$
|
|
|
Actual
|
Required
|
|
Debt to EBITDA
(1)
(Maximum)
|
|
<
|
|
Interest Coverage (Minimum)
|
|
>
|
(1) |
|
(In thousands)
|
2021
|
2020
|
||||||
U.S. credit facilities
|
$
|
|
$
|
|
||||
Current maturities of long-term debt
|
|
|
||||||
Loans of foreign subsidiaries
|
|
|
||||||
Total
|
$
|
|
$
|
|
(In thousands except fair value)
|
Shares
|
Grant Date
Weighted Average
Fair Value
|
Aggregate Intrinsic
Value
|
|||||||||
Outstanding at
December 31
,
2018
|
|
$
|
|
$
|
|
|||||||
Granted
|
|
|
||||||||||
Vested
|
(
|
)
|
|
|||||||||
Cancelled
|
(
|
)
|
|
|||||||||
Outstanding at
December 31
,
2019
|
|
|
|
|||||||||
Granted
|
|
|
||||||||||
Vested
|
(
|
)
|
|
|||||||||
Cancelled
|
(
|
)
|
|
|||||||||
Outstanding at
December 31
,
2020
|
|
|
|
|||||||||
Granted
|
|
|
||||||||||
Vested
|
(
|
)
|
|
|||||||||
Cancelled
|
(
|
)
|
|
|||||||||
Outstanding at
December 31
,
2021
|
|
$
|
|
$
|
|
(In thousands)
|
2021
|
2020
|
||||||
Benefit obligation at beginning of year
|
$
|
|
$
|
|
||||
Service cost
|
|
|
||||||
Interest cost
|
|
|
||||||
Foreign currency exchange rate changes
|
(
|
)
|
|
|||||
Benefits and settlements paid
|
(
|
)
|
(
|
)
|
||||
Amendments
|
|
|
||||||
Actuarial (gain) loss
|
(
|
)
|
|
|||||
Benefit obligation at end of year
|
|
|
||||||
Plan assets at beginning of year
|
|
|
||||||
Company contributions
|
|
|
||||||
Foreign currency exchange rate changes
|
(
|
)
|
|
|||||
Benefits paid
|
(
|
)
|
(
|
)
|
||||
Settlement payments
|
(
|
) |
|
|||||
Actual (loss) gain on plan assets
|
(
|
)
|
|
|||||
Plan assets at end of year
|
|
|
||||||
Funded status
|
$
|
(
|
)
|
$
|
(
|
)
|
||
Accumulated benefit obligation
|
$
|
|
$
|
|
(In thousands)
|
2021
|
2020
|
||||||
Accrued employee and retiree benefits
|
$
|
(
|
)
|
$
|
(
|
)
|
||
Other accrued expenses
|
(
|
)
|
(
|
)
|
||||
Other assets
|
|
|
||||||
Net liability
|
$
|
(
|
)
|
$
|
(
|
)
|
(In thousands)
|
2021
|
2020
|
2019
|
|||||||||
Service cost
|
$
|
|
$
|
|
$
|
|
||||||
Interest cost
|
|
|
|
|||||||||
Expected return on plan assets
|
(
|
)
|
(
|
)
|
(
|
)
|
||||||
Recognized actuarial loss (gain)
|
|
|
(
|
)
|
||||||||
Settlement income
|
(
|
)
|
|
|
||||||||
Defined benefit expense
|
$
|
|
$
|
|
$
|
|
|
2021
|
2020
|
||||||
Discount rate
|
|
%
|
|
%
|
||||
Expected return on plan assets
|
|
%
|
|
%
|
||||
Rate of compensation increase
|
|
%
|
|
%
|
|
2021
|
2020
|
2019
|
|||||||||
Discount rate
|
|
%
|
|
%
|
|
%
|
||||||
Expected return on plan assets
|
|
%
|
|
%
|
|
%
|
||||||
Rate of compensation increase
|
|
%
|
|
%
|
|
%
|
(In thousands)
|
2021
|
2020
|
||||||
Unrecognized net actuarial loss
|
$
|
|
$
|
|
||||
Prior service cost
|
|
|
||||||
Total before tax effects
|
$
|
|
$
|
|
(In thousands)
|
2021
|
2020
|
2019
|
|||||||||
Net actuarial gain (loss) arising during the period
|
$
|
|
$
|
(
|
)
|
$
|
(
|
)
|
||||
Prior service cost
|
|
(
|
)
|
|
||||||||
Amortization of actuarial loss (gain), included in defined benefit expense
|
|
|
(
|
)
|
||||||||
Pension adjustment, net of tax
|
$
|
|
$
|
(
|
)
|
$
|
(
|
)
|
|
Fair Value
as of
December 31,
|
Fair Value Measurements at
December 31, 2021
Using Fair Value Hierarchy
|
Fair Value
as of
December 31,
|
Fair Value Measurements at
December 31, 2020
Using Fair Value Hierarchy
|
||||||||||||||||||||||||||||
(In thousands)
|
2021
|
Level 1
|
Level 2
|
Level 3
|
2020
|
Level 1
|
Level 2
|
Level 3
|
||||||||||||||||||||||||
Equity Funds
|
||||||||||||||||||||||||||||||||
Domestic
|
$
|
|
$
|
|
$
|
|
$
|
|
$
|
|
$
|
|
$
|
|
$
|
|
||||||||||||||||
International
|
|
|
|
|
|
|
|
|
||||||||||||||||||||||||
International Fixed Income Funds
|
|
|
|
|
|
|
|
|
||||||||||||||||||||||||
Other investments
|
|
|
|
|
|
|
|
|
||||||||||||||||||||||||
Total assets at fair value
|
$
|
|
$
|
|
$
|
|
$
|
|
$
|
|
$
|
|
$
|
|
$
|
|
Level 1: |
Observable inputs that reflect quoted prices (unadjusted) for identical assets or liabilities in active markets.
|
Level 2: |
Inputs other than quoted prices included in Level 1 that are observable for the asset or liability through corroboration with observable market data.
|
Level 3: |
Unobservable inputs that reflect the reporting entity’s own assumptions.
|
(In thousands)
|
Cash Flow
Hedges
(1)
|
Pension
Items
(1)
|
Foreign Currency
Items
|
Total
|
||||||||||||
Balance as of
December 31
,
2018
|
$
|
|
$
|
|
$
|
(
|
)
|
$
|
(
|
)
|
||||||
Other comprehensive income (loss) before reclassifications
|
(
|
)
|
(
|
)
|
|
|
||||||||||
Amounts reclassified from OCI
|
(
|
)
|
(
|
)
|
|
(
|
)
|
|||||||||
Balance as of
December 31
,
2019
|
$
|
(
|
)
|
$
|
(
|
)
|
$
|
(
|
)
|
$
|
(
|
)
|
||||
Other comprehensive income (loss) before reclassifications
|
(
|
)
|
(
|
)
|
|
|
||||||||||
Amounts reclassified from OCI
|
|
|
(
|
)
|
(
|
)
|
||||||||||
Balance as of
December 31
,
2020
|
$
|
|
$
|
(
|
)
|
$
|
(
|
)
|
$
|
(
|
)
|
|||||
Other comprehensive income (loss) before reclassifications
|
|
|
(
|
)
|
(
|
)
|
||||||||||
Amounts reclassified from OCI
|
(
|
)
|
|
|
|
|||||||||||
Balance as of
December 31
,
2021
|
$
|
|
$
|
(
|
)
|
$
|
(
|
)
|
$
|
(
|
)
|
(1) |
|
(In thousands)
|
2021
|
2020
|
2019
|
|||||||||
United States
|
$
|
|
$
|
|
$
|
|
||||||
Foreign
|
|
|
|
|||||||||
Total
|
$
|
|
$
|
|
$
|
|
(In thousands)
|
2021
|
2020
|
2019
|
|||||||||
Current income tax expense:
|
||||||||||||
Federal
|
$
|
|
$
|
|
$
|
|
||||||
State
|
|
|
|
|||||||||
Foreign
|
|
|
|
|||||||||
|
|
|
|
|||||||||
Deferred expense (benefit):
|
||||||||||||
Federal
|
(
|
)
|
(
|
)
|
(
|
)
|
||||||
State
|
(
|
)
|
(
|
)
|
|
|||||||
Foreign
|
(
|
)
|
(
|
)
|
(
|
)
|
||||||
|
(
|
)
|
(
|
)
|
(
|
)
|
||||||
Income taxes
|
$
|
|
$
|
|
$
|
|
|
2021
|
2020
|
2019
|
|||||||||
Taxes at statutory rate
|
|
%
|
|
%
|
|
%
|
||||||
State income taxes, net of federal income tax benefit
|
|
|
|
|||||||||
Tax credits
|
(
|
)
|
(
|
)
|
(
|
)
|
||||||
Taxes on foreign earnings
|
|
|
|
|||||||||
Global Intangible Low-Taxed Income
|
|
|
|
|||||||||
Foreign Derived Intangible Income
|
(
|
)
|
(
|
)
|
(
|
)
|
||||||
Loss on balance sheet hedge
|
|
|
|
|
||||||||
Resolution of prior years’ tax matters
|
(
|
)
|
(
|
)
|
(
|
)
|
||||||
Valuation allowance adjustments
|
(
|
)
|
(
|
)
|
(
|
)
|
||||||
Other, net
|
(
|
)
|
(
|
)
|
|
|||||||
Effective tax rate
|
|
%
|
|
%
|
|
%
|
(In thousands)
|
2021
|
2020
|
||||||
Deferred tax assets:
|
||||||||
Benefit plans
|
$
|
|
$
|
|
||||
Liabilities and reserves
|
|
|
||||||
Operating loss and credit carryovers
|
|
|
||||||
Other
|
|
|
||||||
Gross deferred tax assets
|
|
|
||||||
Valuation allowance
|
(
|
)
|
(
|
)
|
||||
Deferred tax assets
|
|
|
||||||
Deferred tax liabilities:
|
||||||||
Property, plant, and equipment
|
(
|
)
|
(
|
)
|
||||
Goodwill
|
(
|
)
|
(
|
)
|
||||
Deferred tax liabilities
|
(
|
)
|
(
|
)
|
||||
Net deferred tax assets
|
$
|
|
$
|
|
(In thousands)
|
2021
|
2020
|
||||||
Balance at beginning of year
|
$
|
|
$
|
|
||||
Increases for tax positions taken in the current year
|
|
|
||||||
Increases for tax positions taken in prior years
|
|
|
||||||
Decreases related to settlements with tax authorities
|
(
|
)
|
(
|
)
|
||||
Decreases as a result of lapse of the applicable statutes of limitations
|
(
|
)
|
(
|
)
|
||||
Foreign currency exchange rate changes
|
(
|
)
|
|
|||||
Balance at the end of year
|
$
|
|
$
|
|
(In thousands)
|
Flavors &
Extracts
|
Color
|
Asia Pacific
|
Corporate
& Other
|
Consolidated
|
|||||||||||||||
2021
:
|
||||||||||||||||||||
Revenue from external customers
|
$
|
|
$
|
|
$
|
|
$
|
|
$
|
|
||||||||||
Intersegment revenue
|
|
|
|
|
|
|||||||||||||||
Total revenue
|
|
|
|
|
|
|||||||||||||||
|
||||||||||||||||||||
Operating income (loss)
|
|
|
|
(
|
)
|
|
||||||||||||||
Interest expense
|
|
|
|
|
|
|||||||||||||||
Earnings (loss) before income taxes
|
|
|
|
(
|
)
|
|
||||||||||||||
|
||||||||||||||||||||
Assets
|
|
|
|
|
|
|||||||||||||||
Capital expenditures
|
|
|
|
|
|
|||||||||||||||
Depreciation and amortization
|
|
|
|
|
|
|||||||||||||||
|
||||||||||||||||||||
2020
:
|
||||||||||||||||||||
Revenue from external customers
|
$
|
|
$
|
|
$
|
|
$
|
|
$
|
|
||||||||||
Intersegment revenue
|
|
|
|
|
|
|||||||||||||||
Total revenue
|
|
|
|
|
|
|||||||||||||||
|
||||||||||||||||||||
Operating income (loss)
|
|
|
|
(
|
)
|
|
||||||||||||||
Interest expense
|
|
|
|
|
|
|||||||||||||||
Earnings (loss) before income taxes
|
|
|
|
(
|
)
|
|
||||||||||||||
|
||||||||||||||||||||
Assets
|
|
|
|
|
|
|||||||||||||||
Capital expenditures
|
|
|
|
|
|
|||||||||||||||
Depreciation and amortization
|
|
|
|
|
|
|||||||||||||||
|
||||||||||||||||||||
2019
:
|
||||||||||||||||||||
Revenue from external customers
|
$
|
|
$
|
|
$
|
|
$
|
|
$
|
|
||||||||||
Intersegment revenue
|
|
|
|
|
|
|||||||||||||||
Total revenue
|
|
|
|
|
|
|||||||||||||||
|
||||||||||||||||||||
Operating income (loss)
|
|
|
|
(
|
)
|
|
||||||||||||||
Interest expense
|
|
|
|
|
|
|||||||||||||||
Earnings (loss) before income taxes
|
|
|
|
(
|
)
|
|
||||||||||||||
|
||||||||||||||||||||
Assets
|
|
|
|
|
|
|||||||||||||||
Capital expenditures
|
|
|
|
|
|
|||||||||||||||
Depreciation and amortization
|
|
|
|
|
|
(In thousands)
|
Flavors &
Extracts
|
Color
|
Asia Pacific
|
Corporate
& Other
|
Consolidated
|
|||||||||||||||
2021
:
|
||||||||||||||||||||
Revenue from external customers:
|
||||||||||||||||||||
North America
|
$
|
|
$
|
|
$
|
|
$
|
|
$
|
|
||||||||||
Europe
|
|
|
|
|
|
|||||||||||||||
Asia Pacific
|
|
|
|
|
|
|||||||||||||||
Other
|
|
|
|
|
|
|||||||||||||||
Total revenue from external customers
|
$
|
|
$
|
|
$
|
|
$
|
|
$
|
|
||||||||||
Long-lived assets:
|
||||||||||||||||||||
North America
|
$
|
|
$
|
|
$
|
|
$
|
|
$
|
|
||||||||||
Europe
|
|
|
|
|
|
|||||||||||||||
Asia Pacific
|
|
|
|
|
|
|||||||||||||||
Other
|
|
|
|
|
|
|||||||||||||||
Total long-lived assets
|
$
|
|
$
|
|
$
|
|
$
|
|
$
|
|
||||||||||
|
||||||||||||||||||||
2020
:
|
||||||||||||||||||||
Revenue from external customers:
|
||||||||||||||||||||
North America
|
$
|
|
$
|
|
$
|
|
$
|
|
$
|
|
||||||||||
Europe
|
|
|
|
|
|
|||||||||||||||
Asia Pacific
|
|
|
|
|
|
|||||||||||||||
Other
|
|
|
|
|
|
|||||||||||||||
Total revenue from external customers
|
$
|
|
$
|
|
$
|
|
$
|
|
$
|
|
||||||||||
Long-lived assets:
|
||||||||||||||||||||
North America
|
$
|
|
$
|
|
$
|
|
$
|
|
$
|
|
||||||||||
Europe
|
|
|
|
|
|
|||||||||||||||
Asia Pacific
|
|
|
|
|
|
|||||||||||||||
Other
|
|
|
|
|
|
|||||||||||||||
Total long-lived assets
|
$
|
|
$
|
|
$
|
|
$
|
|
$
|
|
||||||||||
|
||||||||||||||||||||
2019
:
|
||||||||||||||||||||
Revenue from external customers:
|
||||||||||||||||||||
North America
|
$
|
|
$
|
|
$
|
|
$
|
|
$
|
|
||||||||||
Europe
|
|
|
|
|
|
|||||||||||||||
Asia Pacific
|
|
|
|
|
|
|||||||||||||||
Other
|
|
|
|
|
|
|||||||||||||||
Total revenue from external customers
|
$
|
|
$
|
|
$
|
|
$
|
|
$
|
|
||||||||||
Long-lived assets:
|
||||||||||||||||||||
North America
|
$
|
|
$
|
|
$
|
|
$
|
|
$
|
|
||||||||||
Europe
|
|
|
|
|
|
|||||||||||||||
Asia Pacific
|
|
|
|
|
|
|||||||||||||||
Other
|
|
|
|
|
|
|||||||||||||||
Total long-lived assets
|
$
|
|
$
|
|
$
|
|
$
|
|
$
|
|
(In thousands)
|
Flavors &
Extracts
|
Color
|
Asia Pacific
|
Consolidated
|
||||||||||||
2021
:
|
||||||||||||||||
Flavors, Extracts & Flavor Ingredients
|
$
|
|
$
|
|
$
|
|
$
|
|
||||||||
Natural Ingredients
|
|
|
|
|
||||||||||||
Fragrances
|
|
|
|
|
||||||||||||
Yogurt Fruit Preparations
|
|
|
|
|
||||||||||||
Food & Pharmaceutical Colors
|
|
|
|
|
||||||||||||
Personal Care
|
|
|
|
|
||||||||||||
Inks
|
|
|
|
|
||||||||||||
Asia Pacific
|
|
|
|
|
||||||||||||
Intersegment Revenue
|
(
|
)
|
(
|
)
|
(
|
)
|
(
|
)
|
||||||||
Total revenue from external customers
|
$
|
|
$
|
|
$
|
|
$
|
|
||||||||
2020
:
|
||||||||||||||||
Flavors, Extracts & Flavor Ingredients
|
$
|
|
$
|
|
$
|
|
$
|
|
||||||||
Natural Ingredients
|
|
|
|
|
||||||||||||
Fragrances
|
|
|
|
|
||||||||||||
Yogurt Fruit Preparations
|
|
|
|
|
||||||||||||
Food & Pharmaceutical Colors
|
|
|
|
|
||||||||||||
Personal Care
|
|
|
|
|
||||||||||||
Inks
|
|
|
|
|
||||||||||||
Asia Pacific
|
|
|
|
|
||||||||||||
Intersegment Revenue
|
(
|
)
|
(
|
)
|
(
|
)
|
(
|
)
|
||||||||
Total revenue from external customers
|
$
|
|
$
|
|
$
|
|
$
|
|
||||||||
2019
:
|
||||||||||||||||
Flavors, Extracts & Flavor Ingredients
|
$
|
|
$
|
|
$
|
|
$
|
|
||||||||
Natural Ingredients
|
|
|
|
|
||||||||||||
Fragrances
|
|
|
|
|
||||||||||||
Yogurt Fruit Preparations
|
|
|
|
|
||||||||||||
Food & Pharmaceutical Colors
|
|
|
|
|
||||||||||||
Personal Care
|
|
|
|
|
||||||||||||
Inks
|
|
|
|
|
||||||||||||
Asia Pacific
|
|
|
|
|
||||||||||||
Intersegment Revenue
|
(
|
)
|
(
|
)
|
(
|
)
|
(
|
)
|
||||||||
Total revenue from external customers
|
$
|
|
$
|
|
$
|
|
$
|
|
(In thousands)
|
December 31, 2020
|
|||
Assets held for sale:
|
||||
Trade accounts receivable, less allowance for losses of $
|
$
|
|
||
Inventories
|
|
|||
Prepaid expenses and other current assets
|
|
|||
Property, Plant, and Equipment, net
|
|
|||
Intangible assets
|
|
|||
Assets held for sale
|
$
|
|
||
Liabilities held for sale:
|
||||
Trade accounts payable
|
$
|
|
||
Accrued salaries, wages, and withholdings from employees
|
|
|||
Other accrued expenses
|
|
|||
Liabilities held for sale
|
$
|
|
(In thousands)
|
Yogurt Fruit Preparations
|
Fragrances
|
Inks
|
Corporate/
Other
|
Consolidated
|
|||||||||||||||
Non-cash impairment charges – Selling and administrative expenses
|
$
|
(
|
)
|
$
|
|
$
|
|
$
|
|
$
|
|
|||||||||
Non-cash charges – Cost of products sold
|
|
|
(
|
)
|
|
|
||||||||||||||
Reclassification of foreign currency translation and related items – Selling and administrative expenses
|
|
|
|
|
|
|||||||||||||||
Other costs - Selling and administrative expenses
(1)
|
|
|
(
|
)
|
|
|
||||||||||||||
Total
|
$
|
(
|
)
|
$
|
|
$
|
(
|
)
|
$
|
|
$
|
|
|
(1)
|
|
(In thousands)
|
Yogurt Fruit Preparations
|
Fragrances
|
Inks
|
Corporate/
Other
|
Consolidated
|
|||||||||||||||
Non-cash impairment charges – Selling and administrative expenses
|
$
|
|
$
|
|
$
|
|
$
|
(
|
)
|
$
|
|
|||||||||
Non-cash charges – Cost of products sold
|
|
|
(
|
)
|
|
|
||||||||||||||
Reclassification of foreign currency translation and related items – Selling and administrative expenses
|
|
|
(
|
)
|
|
(
|
)
|
|||||||||||||
Other costs - Selling and administrative expenses
(1)
|
|
|
|
|
|
|||||||||||||||
Total
|
$
|
|
$
|
|
$
|
|
$
|
|
$
|
|
|
(1)
|
|
(In thousands)
|
Yogurt Fruit Preparations
|
Fragrances
|
Inks
|
Corporate/
Other
|
Consolidated
|
|||||||||||||||
Non-cash impairment charges – Selling and administrative expenses
|
$
|
|
$
|
|
$
|
|
$
|
|
$
|
|
||||||||||
Non-cash charges – Cost of products sold
|
|
|
|
|
|
|||||||||||||||
Other costs - Selling and administrative expenses
(1)
|
|
|
|
|
|
|||||||||||||||
Other costs – Cost of products sold
(2)
|
|
|
|
|
|
|||||||||||||||
Total
|
$
|
|
$
|
|
$
|
|
$
|
|
$
|
|
|
(1)
|
|
|
(2)
|
|
(In thousands)
|
Flavors & Extracts
|
Color
|
Asia
Pacific
|
Consolidated
|
||||||||||||
Employee separation
|
$
|
(
|
)
|
$
|
(
|
)
|
$
|
(
|
)
|
$
|
(
|
)
|
||||
Other income
(1)
|
|
(
|
)
|
|
(
|
)
|
||||||||||
Other costs
(2)
|
|
|
|
|
||||||||||||
Total
|
$
|
(
|
)
|
$
|
(
|
)
|
$
|
(
|
)
|
$
|
(
|
)
|
|
(1) |
|
|
(2) |
|
(In thousands)
|
Flavors & Extracts
|
Color
|
Asia
Pacific
|
Consolidated
|
||||||||||||
Employee separation
|
$
|
|
$
|
|
$
|
|
$
|
|
||||||||
Other costs
(1)
|
|
|
|
|
||||||||||||
Total
|
$
|
|
$
|
|
$
|
|
$
|
|
(1) |
|
(In thousands)
|
Selling and Administrative Expenses
|
Cost of Products Sold
|
Consolidated
|
|||||||||
Employee separation
|
$
|
|
$
|
|
$
|
|
||||||
Other costs
(1)
|
|
|
|
|||||||||
Total
|
$
|
|
$
|
|
$
|
|
(1) |
|
Report of Independent Registered Public Accounting Firm
|
The Board of Directors and Shareholders of
Sensient Technologies Corporation
Milwaukee, Wisconsin
|
|
Opinion on the Financial Statements
We have audited the accompanying consolidated balance sheets of Sensient Technologies Corporation and subsidiaries (the Company) as of
December 31, 2021 and 2020, the related consolidated statements of earnings, comprehensive income, shareholders’ equity, and cash flows for each of the three years in the period ended December 31, 2021, and the related notes and the financial
statement schedule listed in the Index at Item 15 (collectively referred to as the “consolidated financial statements”). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of
the Company at December 31, 2021 and 2020, and the consolidated results of its operations and its cash flows for each of the three years in the period ended December 31, 2021, in conformity with U.S. generally accepted accounting principles.
|
We have also audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the
Company’s internal control over financial reporting as of December 31, 2021, based on the criteria established in the Internal Control-Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (2013
framework) and our report dated February 18, 2022 expressed an unqualified opinion thereon.
Basis for Opinion
These financial statements are the responsibility of the Company’s management. Our responsibility is to express an opinion on the Company’s
financial statements based on our audits. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules
and regulations of the Securities and Exchange Commission and the PCAOB.
We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain
reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. Our audits included performing procedures to assess the risks of material misstatement of the financial statements,
whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included
evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.
|
|
|
Income Taxes--Valuation Allowances for Deferred Tax Assets
|
Description of the Matter
|
|
As described in Note 11 to the consolidated financial statements, at December 31, 2021, the Company had gross deferred tax assets of
$106.0 million, $68.6 million of which relate to net operating losses (NOLs), foreign tax credits and other tax credits reduced by a $36.9 million valuation allowance. Deferred tax assets are reduced by a valuation allowance if, based
upon the weight of all available evidence, it is more likely than not that some portion, or all, of the deferred tax assets will not be realized.
Management’s analysis of the realizability of its deferred tax assets related to NOLs, foreign tax credits and other tax credits was
significant to our audit because the amounts are material to the financial statements and the assessment process related to the realizability of these deferred tax assets is complex, and involves significant judgments that include
projections of income, sources of income and tax planning strategies.
|
How We Addressed the Matter in Our Audit
|
|
We tested controls relating to the realizability of deferred tax assets, including controls over management’s projections of future
taxable income, the future reversal of existing taxable temporary differences and management’s identification and use of available tax planning strategies.
To test management’s assessment of the realizability of its deferred tax assets related to NOLs, foreign and other tax credits, our
audit procedures included, among others, evaluation of the assumptions used by the Company to develop tax planning strategies and projections of future taxable income by jurisdiction and testing the completeness and accuracy of the
underlying data used in its projections. We involved our tax professionals to evaluate the application of tax law in the Company’s available tax planning strategies and projections of future taxable income. We assessed the historical
accuracy of management’s projections and reconciled the projections of future taxable income with other forecasted financial information prepared by the Company. We also tested the Company’s scheduling of the reversal of existing
temporary taxable differences.
|
Item 12.
|
Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters.
|
Item 15.
|
Exhibit and Financial Statement Schedules.
|
33
|
||
31
|
||
32
|
||
35
|
||
34
|
||
36-59
|
||
Report of Independent Registered Public Accounting Firm
(PCAOB ID:
42
)
|
60
|
Exhibit
Number
|
Description
|
Incorporated by
Reference from
|
Filed
Herewith
|
|||
Sensient Technologies Corporation Amended and Restated Articles of Incorporation
|
Exhibit 3.1 to Current Report on Form 8-K dated July 24, 2017 (Commission File No. 1-7626)
|
|||||
Sensient Technologies Corporation Amended and Restated By-Laws
|
Exhibit 3.1 to Current Report on Form 8-K dated filed February 15, 2022 (Commission File No. 1-7626)
|
|||||
Note Purchase Agreement dated as of April 5, 2013
|
Exhibit 10.1 to Current Report on Form 8-K dated April 5, 2013 (Commission File No. 1-7626)
|
|||||
First Amendment dated as of November 6, 2015 to Note Purchase Agreement dated as of April 5, 2013
|
Exhibit 10.3 to Current Report on Form 8-K dated November 6, 2015 (Commission File No. 1-7626)
|
|||||
Second Amendment dated as of May 3, 2017 to Note Purchase Agreement dated as of April 5, 2013
|
Exhibit 10.4 to Current Report on Form 8-K dated May 5, 2017 (Commission File No. 1-7626)
|
|||||
Third Amendment dated as of June 22, 2018 to Note Purchase Agreement dated as of April 5, 2013
|
Exhibit 4.2(d) to Quarterly Report on Form 10-Q for the quarter ended June 30, 2018 (Commission File No. 1-7626)
|
|
Fourth Amendment dated as of May 6, 2021 to Note Purchase Agreement dated as of April 5, 2013
|
Exhibit 4.1 to Current Report on Form 8-K filed May 11, 2021 (Commission File No. 1-7626)
|
||||
Note Purchase Agreement dated as of November 6, 2015
|
Exhibit 10.2 to Current Report on Form 8-K dated November 6, 2015 (Commission File No. 1-7626)
|
|||||
First Amendment dated as of May 3, 2017 to Note Purchase Agreement dated as of November 6, 2015
|
Exhibit 10.3 to Current Report on Form 8-K dated May 5, 2017 (Commission File No. 1-7626)
|
|||||
Second Amendment dated as of June 22, 2018 to Note Purchase Agreement dated as of November 6, 2015
|
Exhibit 4.3(c) to Quarterly Report on Form 10-Q for the quarter ended June 30, 2018 (Commission File No. 1-7626)
|
|||||
Third Amendment dated as of May 6, 2021 to Note Purchase Agreement dated as of November 6, 2015
|
Exhibit 4.2 to Current Report on Form 8-K filed May 11, 2021 (Commission File No. 1-7626)
|
|||||
Note Purchase Agreement dated as of May 3, 2017
|
Exhibit 10.2 to Current Report on Form 8-K dated May 5, 2017 (Commission File No. 1-7626)
|
|||||
First Amendment dated as of June 22, 2018 to Note Purchase Agreement dated as of May 3, 2017
|
Exhibit 4.4(b) to Quarterly Report on Form 10-Q for the quarter ended June 30, 2018 (Commission File No. 1-7626)
|
|||||
Second Amendment dated as of May 6, 2021 to Note Purchase Agreement dated as of May 3, 2017
|
Exhibit 4.3 to Current Report on Form 8-K filed May 11, 2021 (Commission File No. 1-7626)
|
|||||
Note Purchase Agreement dated as of November 1, 2018
|
Exhibit 10.1 to Current Report on Form 8-K dated November 1, 2018 (Commission File No. 1-7626)
|
|||||
First Amendment dated as of May 6, 2021 to Note Purchase Agreement dated as of November 1, 2018
|
Exhibit 4.4 to Current Report on Form 8-K filed May 11, 2021 (Commission File No. 1-7626)
|
|||||
Description of Sensient Technologies Corporation’s securities registered pursuant to Section 12 of the Securities Exchange Act
|
Exhibit 4.5 to Annual Report on Form 10-K for the fiscal year ended December 31, 2019 (Commission File No. 1-7626)
|
|||||
10
|
Material Contracts
|
|||||
10.1
|
Management Contracts or Compensatory Plans
|
|||||
Executive Employment Contract dated as of February 13, 2020, between Sensient Technologies Corporation and Paul Manning
|
Exhibit 10.1 to Current Report on Form 8-K dated February 13, 2020 (Commission File No. 1-7626)
|
|||||
Form of Change of Control Employment and Severance Agreement
|
Exhibit 10.1(b)(3) to Annual Report on Form 10-K for the fiscal year ended December 31, 2011 (Commission File No. 1-7626)
|
|||||
Sensient Technologies Corporation 2012 Non-Employee Directors Stock Plan
|
Exhibit 10.1(c)(2) to Annual Report on Form 10-K for the fiscal year ended December 31, 2014 (Commission File No. 1-7626)
|
Sensient Technologies Corporation Directors’ Deferred Compensation Plan
|
Exhibit 10.1 to Current Report on Form 8-K dated May 28, 2014 (Commission File No. 1-7626)
|
|||||
Sensient Technologies Corporation Non-Employee Directors’ Retirement Plan
|
Exhibit 10.2 to Current Report on Form 8-K dated July 25, 2013 (Commission File No. 1-7626)
|
|||||
Sensient Technologies Corporation Frozen Management Income Deferral Plan
|
Exhibit 10.5(a) to Quarterly Report on Form 10-Q for the quarter ended September 30, 2008 (Commission File No. 1-7626)
|
|||||
Sensient Technologies Corporation Management Income Deferral Plan
|
Exhibit 10.5(b) to Quarterly Report on Form 10-Q for the quarter ended September 30, 2008 (Commission File No. 1-7626)
|
|||||
Sensient Technologies Corporation Frozen Executive Income Deferral Plan
|
Exhibit 10.4(a) to Quarterly Report on Form 10-Q for the quarter ended September 30, 2008 (Commission File No. 1-7626)
|
|||||
Sensient Technologies Corporation Executive Income Deferral Plan
|
Exhibit 10.4(b) to Quarterly Report on Form 10-Q for the quarter ended September 30, 2008 (Commission File No. 1-7626)
|
|||||
Amended and Restated Sensient Technologies Corporation Rabbi Trust “A” Agreement dated November 30, 2009, between Sensient Technologies Corporation and Wells Fargo Bank,
N.A.
|
Exhibit 10.1(l) to Annual Report on Form 10-K for the fiscal year ended December 31, 2009 (Commission File No. 1-7626)
|
|||||
Amended and Restated Sensient Technologies Corporation Rabbi Trust “B” Agreement dated November 30, 2009, between Sensient Technologies Corporation and Wells Fargo Bank,
N.A.
|
Exhibit 10.1(m) to Annual Report on Form 10-K for the fiscal year ended December 31, 2009 (Commission File No. 1-7626)
|
|||||
Amendment No. 1 to the Amended and Restated Sensient Technologies Corporation Rabbi Trust “B” Agreement
|
Exhibit 10.1(m)(2) to Quarterly Report on Form 10-Q for the quarter ended June 30, 2017 (Commission File No. 1-7626)
|
|||||
Amended and Restated Sensient Technologies Corporation Rabbi Trust “C” Agreement dated November 30, 2009, between Sensient Technologies Corporation and Wells Fargo Bank,
N.A.
|
Exhibit 10.1(n) to Annual Report on Form 10-K for the fiscal year ended December 31, 2009 (Commission File No. 1-7626)
|
|||||
Sensient Technologies Corporation Form of Supplemental Executive Retirement Plan A Agreement
|
Exhibit 10.1(s) to Annual Report on Form 10-K for the fiscal year ended December 31, 2008 (Commission File No. 1-7626)
|
Form of Amendment No. 1 to the Sensient Technologies Corporation Amended and Restated Supplemental Executive Retirement Plan A
|
Exhibit 10.1(s)(2) to Annual Report on Form 10-K for the fiscal year ended December 31, 2010 (Commission file No. 1-7626)
|
|||||
Form of Amendment No. 2 to the Sensient Technologies Corporation Amended and Restated Supplemental Executive Retirement Plan A
|
Exhibit 10.1 to Current Report on Form 8-K dated April 22, 2010 (Commission File No. 1-7626)
|
|||||
Sensient Technologies Corporation Form of Supplemental Executive Retirement Plan B Agreement
|
Exhibit 10.1(t) to Annual Report on Form 10-K for the fiscal year ended December 31, 2008 (Commission File No. 1-7626)
|
|||||
Form of Amendment No. 1 to the Sensient Technologies Corporation Amended and Restated Supplemental Executive Retirement Plan B
|
Exhibit 10.1(t)(2) to Annual Report on Form 10-K for the fiscal year ended December 31, 2010 (Commission File No. 1-7626)
|
|||||
Form of Amendment No. 2 to the Sensient Technologies Corporation Amended and Restated Supplemental Executive Retirement Plan B
|
Exhibit 10.2 to Current Report on Form 8-K dated April 22, 2010 (Commission File No. 1-7626)
|
|||||
Sensient Technologies Frozen Supplemental Benefit Plan
|
Exhibit 10.6(a) to Quarterly Report on Form 10-Q for the quarter ended September 30, 2008 (Commission File No. 1-7626)
|
|||||
Sensient Technologies Supplemental Benefit Plan
|
Exhibit 10.6(b) to Quarterly Report on Form 10-Q for the quarter ended September 30, 2008 (Commission File No. 1-7626)
|
|||||
Sensient Technologies Corporation Policy on Recovery of Incentive Compensation from Executives
|
Exhibit 10.1 to Current Report on Form 8-K dated December 8, 2011 (Commission File No. 1-7626)
|
|||||
Form of Performance Stock Unit Agreement
|
Exhibit 10.3 to Current Report on Form 8-K dated May 28, 2014 (Commission File No. 1-7626)
|
|||||
Form of Restricted Stock Agreement
|
Exhibit 10.1 to Current Report on Form 8-K dated December 10, 2020 (Commission File No. 1-7626)
|
|||||
Form of Restricted Stock Unit Agreement
|
Exhibit 10.2 to Current Report on Form 8-K dated December 10, 2020 (Commission File No. 1-7626)
|
|||||
Sensient Technologies Corporation 2017 Stock Plan
|
Appendix B to Definitive Proxy Statement filed on Schedule 14A on March 10, 2017 (Commission File No. 1-7626)
|
|||||
Sensient Technologies Management Incentive Compensation Plan, as amended on February 10, 2022
|
X
|
Third Amended and Restated Credit Agreement dated as of May 5, 2021
|
|
Exhibit 10.1 to Current Report on Form 8-K filed May 11, 2021 (Commission File No. 1-7626)
|
|
|||
Receivables Sale Agreement dated as of October 3, 2016
|
Exhibit 10.1 to Current Report on Form 8-K dated October 3, 2016 (Commission File No. 1-7626)
|
|||||
Amendment No. 1 to the Receivables Sale Agreement, dated as of October 2, 2017
|
Exhibit 10.1 to Current Report on Form 8-K dated October 2, 2017 (Commission File No. 1-7626)
|
|||||
Receivables Purchase Agreement dated as of October 3, 2016
|
Exhibit 10.2 to Current Report on Form 8-K dated October 3, 2016 (Commission File No. 1-7626)
|
|||||
Amendment No. 1 to the Receivables Purchase Agreement and Performance Undertaking, dated as of October 2, 2017
|
Exhibit 10.2 to Current Report on Form 8-K dated October 2, 2017 (Commission File No. 1-7626)
|
|||||
Amendment No. 2 to Receivables Purchase Agreement, dated as of June 26, 2018
|
Exhibit 10.5(c) to Quarterly Report on Form 10-Q for the quarter ended June 30, 2018 (Commission File No. 1-7626)
|
|||||
Amendment No. 3 to Receivables Purchase Agreement, dated as of October 1, 2018
|
Exhibit 10.1 to Current Report on Form 8-K dated October 1, 2018 (Commission File No. 1-7626)
|
|||||
Amendment No. 4 to Receivables Purchase Agreement, dated as of October 1, 2019
|
Exhibit 10.1 to Current Report on Form 8-K dated October 7, 2019 (Commission File No. 1-7626)
|
|||||
Amendment No. 5 to Receivables Purchase Agreement, dated as of October 1, 2020
|
Exhibit 10.1 to Current Report on Form 8-K dated October 1, 2020 (Commission File No. 1-7626)
|
|||||
Amendment No. 6 to Receivables Purchase Agreement, dated as of November 12, 2020
|
Exhibit 10.4(g) to Annual Report on Form 10-K for the fiscal year ended December 31, 2020 (Commission File No. 1-7626)
|
|||||
Amendment No. 7 to Receivables Purchase Agreement, dated as of October 1, 2021
|
Exhibit 10.1 to Current Report on Form 8-K filed October 5, 2021 (Commission File No. 1-7626)
|
|||||
Performance Undertaking made as of October 3, 2016
|
Exhibit 10.3 to Current Report on Form 8-K dated October 3, 2016 (Commission File No. 1-7626)
|
|||||
Subsidiaries of the Registrant
|
X
|
|||||
Consent of Ernst & Young LLP
|
X
|
Certifications of Sensient’s President and Chief Executive Officer and Senior Vice President and Chief Financial Officer, pursuant to Rule 13a-14(a) of the Exchange Act
|
X
|
|||||
Certifications of Sensient’s President and Chief Executive Officer and Senior Vice President and Chief Financial Officer, pursuant to 18 United States Code § 1350
|
X
|
|||||
101.INS*
|
Inline Instance Document
|
X
|
||||
101.SCH*
|
Inline XBRL Taxonomy Extension Schema Document
|
X
|
||||
101.CAL*
|
Inline XBRL Taxonomy Extension Calculation Linkbase Document
|
X
|
||||
101.DEF*
|
Inline XBRL Taxonomy Extension Definition Linkbase Document
|
X
|
||||
101.LAB*
|
Inline XBRL Taxonomy Extension Label Linkbase Document
|
X
|
||||
101.PRE*
|
Inline XBRL Taxonomy Extension Presentation Linkbase Document
|
X
|
||||
104
|
Cover Page Interactive Data File (formatted as inline XBRL and contained in Exhibit 101)
|
Valuation Accounts Deducted in the Balance Sheet From the Assets to Which They Apply
|
Balance
at Beginning
of Period
|
Additions
Charged to
Costs and
Expenses
|
Additions
Recorded
During
Acquisitions
|
Deductions
(A)
|
Balance at
End of
Period
|
|||||||||||||||
2019
Allowance for losses:
Trade accounts receivable
|
$
|
|
$
|
|
$
|
|
$
|
|
$
|
|
||||||||||
|
||||||||||||||||||||
2020
Allowance for losses:
Trade accounts receivable
|
$
|
|
$
|
|
$
|
|
$
|
|
$
|
|
||||||||||
|
||||||||||||||||||||
2021
Allowance for losses:
Trade accounts receivable
|
$
|
|
$
|
|
$
|
|
$
|
|
$
|
|
||||||||||
(A)
|
SENSIENT TECHNOLOGIES CORPORATION
|
|
/s/ John J. Manning
|
|
John J. Manning
|
|
Senior Vice President, General Counsel and Secretary
|
|
Dated: February 18, 2022
|
/s/ Paul Manning
|
/s/ Sharad P. Jain
|
Paul Manning
|
Sharad P. Jain
|
Chairman of the Board, President and
|
Director
|
Chief Executive Officer
|
|
/s/ Stephen J. Rolfs
|
/s/ Donald W. Landry
|
Stephen J. Rolfs
|
Donald W. Landry
|
Senior Vice President and
|
Director
|
Chief Financial Officer
|
|
/s/ Tobin Tornehl
|
/s/ Deborah McKeithan-Gebhardt
|
Tobin Tornehl
|
Deborah McKeithan-Gebhardt
|
Vice President, Controller and
|
Director
|
Chief Accounting Officer
|
|
/s/ Joseph Carleone
|
/s/ Scott Morrison
|
Joseph Carleone
|
Scott Morrison
|
Director
|
Director
|
/s/ Edward H. Cichurski
|
/s/ Elaine R. Wedral
|
Edward H. Cichurski
|
Elaine R. Wedral
|
Director
|
Director
|
/s/ Mario Ferruzzi
|
/s/ Essie Whitelaw
|
Mario Ferruzzi
|
Essie Whitelaw
|
Director
|
Director
|
/s/ Carol R. Jackson
|
|
Carol R. Jackson
|
|
Director
|
No information found
* THE VALUE IS THE MARKET VALUE AS OF THE LAST DAY OF THE QUARTER FOR WHICH THE 13F WAS FILED.
FUND | NUMBER OF SHARES | VALUE ($) | PUT OR CALL |
---|
DIRECTORS | AGE | BIO | OTHER DIRECTOR MEMBERSHIPS |
---|
No information found
Customers
Customer name | Ticker |
---|---|
The Estée Lauder Companies Inc. | EL |
International Flavors & Fragrances Inc. | IFF |
Pilgrim's Pride Corporation | PPC |
No Suppliers Found
Price
Yield
Owner | Position | Direct Shares | Indirect Shares |
---|